A Combination of Two Currently Approved Drugs to Enhance the Treatment of Schizophrenia

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Study of a medication for the treatment of Schizophrenia in patients who are already taking Abilify, Risperdal, Seroquel, Zyprexa

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company
• Treatments: Atomoxetine Hydrochloride; Olanzapine

Criteria

Inclusion Criteria:

• Must have a clinical diagnosis of Schizophrenia

• Must be at least 18 years of age and not older than 55 years of age

• Must have been stable on a dose of Abilify, Risperdal, Seroquel, or Zyprexa for the past 8 weeks

• Women of childbearing potential must be using a medically accepted means of contraception

• Must be able to swallow capsules

Exclusion Criteria:

• Has serious health problems other than Schizophrenia

• Takes an antidepressant for depression

• Takes insulin for diabetes

• Have a history of alcohol or drug dependence (except for nicotine and caffeine) within the past 6 months